KLP Kapitalforvaltning AS Has $2.26 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• KLP Kapitalforvaltning AS increased its stake in Lantheus Holdings, Inc. by 37.4%, now owning 23,123 shares valued at approximately $2,257,000.
• Insiders, including Director Mary Anne Heino, have recently sold shares, with Heino selling 26,066 shares valued at around $2 million, decreasing her ownership by 7.56%.
• Wall Street analyst ratings for Lantheus are mostly positive, with a current average rating of "Moderate Buy" and an average price target of $131.20.

KLP Kapitalforvaltning AS lifted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 37.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,123 shares of the medical equipment provider's stock after purchasing an additional 6,300 shares during the quarter. KLP Kapitalforvaltning AS's holdings in Lantheus were worth $2,257,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State of Michigan Retirement System grew its holdings in shares of Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock worth $1,620,000 after buying an additional 100 shares in the last quarter. Signaturefd LLC grew its holdings in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares in the last quarter. Foundry Partners LLC grew its holdings in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Lantheus by 2.1% in the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 139 shares during the period. Finally, Moody National Bank Trust Division grew its holdings in shares of Lantheus by 1.0% in the first quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after purchasing an additional 141 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Down 0.2%

Shares of LNTH stock traded down $0.15 on Tuesday, hitting $72.26. The stock had a trading volume of 89,449 shares, compared to its average volume of 1,010,586. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of 20.50 and a beta of 0.12. The stock's 50 day moving average is $77.94 and its 200-day moving average is $88.52. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. Lantheus Holdings, Inc. has a 52-week low of $69.12 and a 52-week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same quarter last year, the company earned $1.69 earnings per share. The company's revenue was up .8% compared to the same quarter last year. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on LNTH shares. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley decreased their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Truist Financial decreased their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, William Blair reissued a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.20.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.